Corbus Pharmaceuticals announced that they have entered into a strategic collaboration with Kaken Pharmaceutical Co. for the development and commercialization in Japan of Corbus’ investigational drug lenabasum for the treatment of systemic sclerosis and dermatomyositis, two rare and serious autoimmune diseases. Under the terms of the agreement, Kaken receives an exclusive license to commercialize and market lenabasum in Japan for systemic sclerosis and dermatomyositis. Kaken will make an upfront payment to Corbus of $27M. Corbus will be eligible to receive in addition up to $173M upon achievement of certain regulatory, development and sales milestones as well as double-digit royalties. Current patient numbers for systemic sclerosis and dermatomyositis1 in Japan are 28,000 and 9,000, respectively, according to the companies. Yuval Cohen, PhD., CEO of Corbus, said, “Kaken is a well-regarded leader in rare autoimmune diseases in Japan with a proud history of scientific and medical innovation. By working together, we believe we can expand the Japanese footprint for lenabasum alongside Corbus’ ongoing efforts in the U.S. and E.U. This collaboration is an important next step in achieving our vision of becoming the global leader in treating inflammatory diseases by focusing on the endocannabinoid system.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.